

Dopamine Type-I Receptor Binding in Major Depressive Disorder Assessed Using Positron Emission Tomography and [^{11}C]NNC-112

Dara M Cannon^{*1,2}, Jacqueline M Klaver², Summer A Peck², Denise Rallis-Voak², Kristine Erickson² and Wayne C Drevets²

¹Department of Psychiatry, Clinical Sciences Institute, National University of Ireland, Galway, Ireland; ²Mood and Anxiety Disorders Program, Molecular Imaging Branch, National Institutes of Mental Health, NIH, Bethesda, MD, USA

The dopamine type-I receptor has been implicated in major depressive disorder (MDD) by clinical and preclinical evidence from neuroimaging, *post mortem*, and behavioral studies. To date, however, selective *in vivo* assessment of D₁ receptors has been limited to the striatum in MDD samples manifesting anger attacks. We employed the PET radioligand, [^{11}C]NNC-112, to selectively assess D₁ receptor binding in extrastriatal and striatal regions in a more generalized sample of MDD subjects. The [^{11}C]NNC-112 nondisplaceable binding potential (BP_{ND}) was assessed using PET in 18 unmedicated, currently depressed subjects with MDD and 19 healthy controls, and compared between groups using MRI-based region-of-interest analysis. The mean D₁ receptor BP_{ND} was reduced (14%) in the left middle caudate of the MDD group relative to control group ($p < 0.05$). Among the MDD subjects D₁ receptor BP_{ND} in this region correlated negatively with illness duration ($r = -0.53$; $p = 0.02$), and the left-to-right BP_{ND} ratio correlated inversely with anhedonia ratings ($r = -0.65$, $p = 0.0040$). The D₁ receptor BP_{ND} was strongly lateralized in striatal regions ($p < 0.002$ for main effects of hemisphere in accumbens area, putamen, and caudate). In *post hoc* analyses, a group-by-hemisphere-by-gender interaction was detected in the dorsal putamen, which was accounted for by a loss of the normal asymmetry in depressed women ($F = 7.33$, $p = 0.01$). These data extended a previous finding of decreased striatal D₁ receptor binding in an MDD sample manifesting anger attacks to a sample selected more generally according to MDD criteria. Our data also more specifically localized this abnormality in MDD to the left middle caudate, which is the target of afferent neural projections from the orbitofrontal and anterior cingulate cortices where neuropathological changes have been reported in MDD. Finally, D₁ receptor binding was asymmetrical across hemispheres in healthy humans, compatible with evidence that dopaminergic function in the striatum is lateralized during reward processing, voluntary movement, and self-stimulation behavior.

Neuropsychopharmacology (2009) 34, 1277–1287; doi:10.1038/npp.2008.194; published online 22 October 2008

Keywords: caudate; striatum; anhedonia; G-protein-coupled receptor

INTRODUCTION

The central dopaminergic system has been implicated in the modulation of emotional behavior, the pathophysiology of depression, and the mechanisms of antidepressant drugs, by clinical and preclinical evidence (Drevets *et al*, 1999; Nestler and Carlezon, 2006; Nutt *et al*, 2006). In experimental animals the dopaminergic projections from the ventral tegmental area (VTA) to the nucleus accumbens shell and medial prefrontal cortex (PFC) were important in learning associations between operant behaviors or sensory stimuli and reward, and in mediating the reinforcing properties of

drugs of abuse and natural rewards (Wise and Rompre, 1989; Schultz, 1997). These observations lead to the hypothesis that reduced mesocorticolimbic DA function underlies the anhedonia, amotivation, and psychomotor slowing associated with major depression (Swerdlow and Koob, 1987; Fibiger, 1991; Nestler and Carlezon, 2006).

A variety of experimental data support this hypothesis. Reductions in dopaminergic function associated with α -methyl-*para*-tyrosine administration can induce depressive symptoms in susceptible individuals (Bremner *et al*, 2003; Hasler *et al*, 2008). Conversely, dopamine receptor agonists (eg pramipexole) exert antidepressant effects in placebo-controlled studies (Willner, 2000; Zarate *et al*, 2004). In MDD subjects DA turnover appears abnormally decreased, as concentrations of the DA metabolite, homovanillic acid (HVA), consistently are reduced in the cerebrospinal fluid (CSF) and jugular vein plasma *in vivo* (Lambert *et al*, 2000; Willner, 2000)—particularly in depressives who manifest

*Correspondence: Dr DM Cannon, Room 201 Comerford Building, Clinical Sciences Institute, National University of Ireland, Galway, Co-Galway, Ireland, Tel: +353 9149 5692, Fax: +353 9149 4563, E-mail: dara.cannon@nuigalway.ie
Received 8 May 2008; revised 8 September 2008; accepted 16 September 2008

psychomotor retardation or melancholic features (Asberg *et al*, 1984) and in the caudate and accumbens *post mortem* in suicide victims (Bowden *et al*, 1997). Neuroimaging studies of MDD showed reduced [¹¹C]-L-DOPA uptake across the blood-brain barrier (Agren and Reibring, 1994) and increased striatal binding to D₂/D₃ receptor radioligands that were sensitive to endogenous DA concentrations, although these latter findings were limited to cases who showed psychomotor slowing (Ebert *et al*, 1996; Drevets *et al*, 2005). In such cases the elevated D₂/D₃ receptor binding may have reflected either reduced intrasynaptic DA concentrations, or compensatory upregulation of D₂/D₃ receptor density or affinity (Todd *et al*, 1996; Laruelle and Huang, 2001). Nevertheless, studies whose samples were not predominantly composed of psychomotor slowed cases found no difference in D₂/D₃ receptor levels during depression (Klimke *et al*, 1999; Parsey *et al*, 2001; Montgomery *et al*, 2007; Hirvonen *et al*, 2008). Similarly, some (Meyer *et al*, 2001) but not other (Brunswick *et al*, 2003; Argyelan *et al*, 2005; Yang *et al*, 2008) studies of striatal DA transporter (DAT) binding reported reduced availability in MDD subjects *vs* controls.

The specific DA receptor subtypes that mediate dopaminergic function in reward processing, emotional behavior, and depression remain incompletely understood, partly due to the paucity of highly selective agonists and antagonists. In mice phenotypic analysis of DA receptor knockouts identified roles for the D₁, D₂, and D₃ receptor subtypes in mediating dopamine's effects on reward processing and/or emotional behavior. A complex role for D₁ receptors in particular was supported by both preclinical and clinical evidence. In genetically engineered mice deletion of the D₁ receptor attenuated the reinforcing properties of rewarding stimuli (reviewed in Holmes *et al*, 2004). Nevertheless, the euphoric effects of cocaine appeared blunted by D₁ receptor-like antagonist administration in cocaine addicts (Romach *et al*, 1999; Waddington *et al*, 2001; Holmes *et al*, 2004). Moreover, in rats the reduction in sucrose consumption resulting from chronic mild stress, a purported model of anhedonia, was associated with increased D₁ receptor density in the caudate-putamen (but not the accumbens or amygdala) (Papp *et al*, 1994), and in humans with schizophrenia, D₁ receptor antagonists alleviated 'negative' symptoms such as anhedonia and amotivation (Den Boer *et al*, 1995; Karle *et al*, 1995).

With respect to other emotional states, in rats intra-amygdaloid injection of D₁ receptor antagonists exerted anxiolytic effects (de la Mora *et al*, 2005) and impaired retention of inhibitory avoidance learning (fear-based memory) (Lalumiere *et al*, 2004). Moreover, D₁ receptor knockout mice showed deficits in fear extinction and reversal learning (putative correlates of resilience to stress or adaptation to behavioral reinforcement, respectively), and abnormal long-term potentiation of synapses on PFC neurons (El-Ghundi *et al*, 1999, 2001; Huang *et al*, 2004). These data appeared consistent with evidence that an optimal range of D₁ receptor stimulation is required to facilitate working memory, as intracortical administration of either agonists or antagonists for D₁ receptors impairs working memory performance in rodents and primates (Arnsten *et al*, 1994; Williams and Goldman-Rakic, 1995; Granon *et al*, 2000; Robbins, 2000).

In MDD the D₁ receptor has been assessed by genetic, *post mortem* and neuroimaging studies. Although polymorphisms in the human D₁ receptor gene have not been associated specifically with the vulnerability for developing MDD (Koks *et al*, 2006), one study (Severino *et al*, 2005) (but not another (Kato, 2007)) found an association with bipolar disorder (BD). *Post mortem* studies of D₁ receptor binding found no difference in the striatum (Bowden *et al*, 1997) or right amygdala (Klimek *et al*, 2002) in MDD subjects who were unmedicated at the time of death (*n* = 28 and 11, respectively) *vs* controls, although one of these found increased D₁ receptor density and reduced affinity in the accumbens in medicated suicide victims (Bowden *et al*, 1997). Finally, a PET-[¹¹C]SCH-23390 study reported reduced D₁ receptor binding in the striatum bilaterally in 10 depressed MDD subjects with anger attacks (Dougherty *et al*, 2006). It remained unclear whether this finding would generalize to other MDD subtypes. In subjects with BD (*n* = 10), a PET-[¹¹C]SCH-23390 study reported no difference in striatal D₁ receptor binding relative to controls, although only three of the subjects were depressed (Suhara *et al*, 1992). The latter study also reported reduced binding in the frontal cortex of BD subjects, but because ~one-half of [¹¹C]SCH-23390 binding in the frontal cortex is attributable to 5-HT_{2A} receptor binding, this difference remained difficult to interpret (Ekelund *et al*, 2006).

The recent development of a PET radioligand using (+)-5-(7-benzofuranyl)-8-chloro-7-hydroxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (NNC-112), a potent and selective D₁ receptor antagonist, provided sufficiently high specific-to-nonspecific binding ratios to permit meaningful assessment of D₁ receptor binding in both extrastriatal and striatal tissues (Andersen *et al*, 1992; Halldin *et al*, 1998). The current study is the first application of [¹¹C]NNC-112 in investigations of D₁ receptor binding in mood disorders, and the first *in vivo* study of D₁ receptor binding in depressed subjects selected more generally according to the criteria for MDD. We hypothesized that the mean D₁ receptor BP_{ND} would be reduced in the striatum of MDD subjects *vs* controls, based on the data reported in MDD subjects with anger attacks (Dougherty *et al*, 2006). In addition, we sought to more specifically localize D₁ receptor binding abnormalities in MDD using an MRI-based technique previously developed for characterizing the dopaminergic system in striatal subregions (Drevets *et al*, 1999, 2001).

PATIENTS AND METHODS

Participants

Right-handed volunteers 18–55 years of age, who either met DSM-IV criteria for recurrent or chronic MDD in a current major depressive episode (*n* = 18), or had no personal history of a major psychiatric disorder (*n* = 19) were studied (Table 1). Diagnosis was established by an unstructured interview with a psychiatrist and the Structured Clinical Interview for DSM-IV (APA, 1994). Exclusion criteria for all subjects included a history of psychosis, exposure to psychotropic drugs, cigarette smoking, or any medication likely to affect cerebral function within the 3 weeks before scanning (eight for fluoxetine), major medical

Table 1 Demographic and Clinical Characterization of the Study Samples

	Control (n = 19)	MDD (n = 18)
Proportion female (n)	58% (11)	61% (11)
Age (mean ± SD)	31 ± 8.5	31 ± 11
Proportion right-handed (n)	100% (19)	100% (18)
<i>Depression ratings</i>		
MADRS (mean ± SD)	0.47 ± 1.2	22 ± 5.3
IDS-C (mean ± SD)	0.59 ± 1.3	27 ± 6.5
<i>Anxiety rating</i>		
HAM-A (mean ± SD)	0.59 ± 1.2	12 ± 4.3
Anhedonia IDSC ratings (mean ± SD)	0.06 ± 0.2	9.4 ± 3.2
Psychomotor speed (response latency on RVIP)	437 ± 78	491 ± 118
Age –at illness onset (years) (mean ± SD (range))	N/A	19 ± 10 (6–41)
Illness duration (years) (mean ± SD (range))	N/A	12 ± 8.5 (2–32)
Duration of medication free (months) (mean ± SD (range))	N/A	23 ± 35 (4–96)
Treatment naïve (n)	19	11
Subjects with remote history of suicide attempts (n)	0	4
Prior exposure to antipsychotic agent (n)	0	1
Remote history of alcohol (2) or marijuana (1) abuse (n)	0	3
Comorbid anxiety disorder (n)	0	5

MADRS, Montgomery Asberg Depression Rating Scale; HAM-A, Hamilton Rating Scale for Anxiety; IDS-C, Inventory of Depressive Symptoms-Clinician Rated; RVIP, Rapid Visual Information Processing.

or neurological illnesses, lifetime history of substance dependence, substance abuse within 1 year, recent suicidal behavior or serious suicidal ideation, current pregnancy, peri- or postmenopause status. Depressed subjects with secondary anxiety disorders were not excluded. Additional exclusion criteria for the controls included having a first-degree relative with a mood, anxiety, or psychotic disorder. Subjects provided written informed consent as approved by the NIMH IRB.

Data Acquisition and Processing

The severity of depressive symptoms was rated using the Montgomery–Asberg Depression Rating Scale (MADRS) (Montgomery and Asberg, 1979) and the Inventory of Depressive Symptoms–Clinician Version (IDS-C). Anxiety symptoms were rated using the Hamilton Anxiety Rating Scale (HAM-A (Hamilton, 1959)), and anhedonia was assessed using the anhedonia subscale of the IDS-C. Psychomotor speed was assessed using the reaction time measured during performance of the Rapid Visual Information Processing (RVIP) task from the Cambridge Neuropsychological Test Automated Battery (CANTAB; Cambridge Cognition Ltd, Cambridge, UK). These computerized tasks were presented on an Advantech computer (Model PP-120T-RT) with a 10.5 in. touch screen monitor.

PET scans were acquired using a GE-Advance scanner in 3D mode (reconstructed 3D spatial-resolution = 6 mm full-width at half-maximum (FWHM)). The PET data were

reconstructed using a Hanning filter and Gaussian fit scatter correction method. An 8-min transmission scan was acquired using rotating rods of ⁶⁸Ge/⁶⁸Ga, and used to perform measured attenuation correction of the emission image. [¹¹C]NNC-112 was synthesized as described previously (Halldin *et al*, 1998). Following intravenous bolus administration of a mean injected dose = 19.5 ± 1.24 mCi (range 15.5–20.8) of high specific activity [¹¹C]NNC-112, a 90-min dynamic emission scan was acquired as 27 frames of increasing length (number × frame duration (min): 6 × 0.50; 3 × 1.0; 2 × 2.0; 16 × 5.0).

Head motion was minimized during scanning by stabilizing each subject's head position using a thermoplastic mask fixed to the scanner table. In addition, the PET data were corrected for head motion by aligning all frames to a mean image of frames 3 through 8, using AIR (Woods *et al*, 1992) as implemented in Medx (Sensor Systems Inc., Sterling, VA). To provide an anatomical framework for the PET analysis, MRI scans were acquired using a GE 1.5 or 3.0 T scanner and T₁-weighted pulse sequence optimized to enhance tissue-contrast resolution (voxel size = 0.86 × 0.86 × 1.2 mm). The realigned PET frames were coregistered to the anatomical MRI for each subject using fMRIB's Linear Image Registration Tool and a mutual information cost function (Jenkinson and Smith, 2001).

Data Analysis

The D₁ receptor binding parameter estimations were performed voxel-wise using a multilinear reference-tissue model (MRTM) using a receptor-free reference region (cerebellum) without arterial data. The BP_{ND} values thus obtained were proportional to the receptor density (*B*_{max}) and independent of blood flow (*K*₁) (Ichise *et al*, 2003). The value of *k*_{2'} was estimated by the three-parameter MRTM using regions-of-interest (ROI) time-activity curves for the striatum. The *R*₁ images, which reflect relative blood flow, were used for image co-registration with MRI. The generation of parametric BP_{ND} images from the dynamic [¹¹C]NNC-112 PET data was performed in PMOD 2.5 (Mikolajczyk *et al*, 1998).

Hypothesis testing was performed in five striatal ROI defined over the anteroventral striatum (AVS; accumbens area, ventromedial caudate, anteroventral putamen), dorsal caudate (DC), middle caudate (MC), ventral putamen (VP), dorsal putamen (DP), as described previously (Bowden *et al*, 1997; Drevets *et al*, 2001). On the basis of the evidence that DA release during reward processing is lateralized in healthy humans (Martin-Soelch *et al*, 2007; Tomer *et al*, 2008), hemisphere was included as a factor in the analyses. To allow comparison with previously reported negative findings from *post mortem* studies of depression (Klimek *et al*, 2002), we examined binding in the amygdala *post hoc*. Additional exploratory analyses were conducted *post hoc* in cortical regions known to contain moderately high D₁ receptor concentrations and to be implicated in the mesocorticolimbic dopaminergic system and the pathophysiology of MDD (Willner, 1995): right and left insula/lateral orbitofrontal cortex (ie sulcal BA47) (Ongur *et al*, 2003) and anterior cingulate cortex (ACC; including subgenual and pregenual areas). Amygdala, insular and ACC ROI were defined as described in (Cannon *et al*, 2007).

The reference region was defined in the cerebellar cortex, with the ROI situated at least one FWHM ventral to the occipital and temporal cortices, and away from the cerebellar vermis and brain edge.

Statistical Analysis

The mean BP_{ND} for each ROI was compared between groups using a linear mixed model and the heterogeneous compound symmetry covariance matrix performed using SPSS. For ROI where the model indicated significant group effects, *post hoc* comparisons of BP_{ND} across groups were performed using unpaired *t*-tests. In regions where group effects were detected the relationship between D₁ receptor BP_{ND} and clinical ratings of depression, anxiety, and anhedonia were assessed *post hoc* by computing Spearman's bivariate correlation coefficients (ρ , ρ).

RESULTS

The groups did not differ significantly for mean age or gender composition (Table 1). Mean depression, anxiety, and anhedonia ratings were greater ($p < 0.001$, $t = -4$ to -17) in MDD subjects than controls (Table 1). Reaction times on the RVIP did not differ significantly between the MDD and control groups ($t = -1.50$, $p = 0.15$). Performance measured by the number of omission (HC 4.5 ± 2.7 , MDD 6.9 ± 5.5 , $t = -1.64$, $p = 0.12$) or commission errors (HC 0.33 ± 1.29 , MDD 1.35 ± 1.83 , $t = -1.794$, $p = 0.083$) on the RVIP also did not differ significantly between groups. Five MDD subjects had comorbid anxiety disorders (generalized social phobia ($n = 4$), specific phobia ($n = 1$)). Two MDD subjects had a remote history of alcohol abuse and one a remote history of marijuana abuse.

The rank order of the [¹¹C]NNC BP_{ND} values was caudate, putamen > AVS > amygdala > insula > ACC > cerebellum (Table 2), consistent with the relative D₁ receptor densities measured *post mortem* in humans (Cortes et al, 1989).

The mean D₁ receptor BP_{ND} was 14% lower in the left MC of the MDD subjects vs controls ($t = 2.21$, $p = 0.03$; Figures 1 and 2; Table 2). The magnitude of this difference was similar after removing the 3 subjects with a remote history of substance abuse (12.6%), the 7 previously medicated MDD subjects (13.5%), or the 5 subjects with co-morbid phobias (11%). In the remaining ROIs mean D₁ receptor BP_{ND} did not differ between the control and MDD groups (Table 2).

In *post hoc* assessments, a main effect of hemisphere was evident in several regions (Figures 1 and 3), including AVS ($F = 87.8$, $p = 8.01e^{-11}$), VP ($F = 8.84$, $p = 3.10e^{-2}$), DP ($F = 25.5$, $p = 1.56e^{-5}$), MC ($F = 308$, $p = 1.09e^{-5}$), and DC ($F = 98.5$, $p = 1.77e^{-4}$). A group-by-gender-by-hemisphere interaction ($F = 7.33$, $p = 0.011$) was detected in the DP, which was accounted for by a greater interhemispheric difference in BP_{ND} in female controls vs female MDD subjects (Figure 4). This interaction remained significant after including age as a covariate, or after removing from analysis the subjects who had a remote history of substance abuse ($F = 4.44$, $p = 0.044$), previous psychotropic medication exposure ($F = 6.17$, $p = 0.020$) or comorbid phobia ($F = 5.83$, $p = 0.023$).

Table 2 The Mean and Standard Deviation of Regional [¹¹C]NNC-112 Binding Potential Values

Region	Healthy control		Major depressive disorder		Group difference	
	Mean	SD	Mean	SD	t	p
VP						
Right	2.41	0.47	2.34	0.42	0.48	0.64
Left	2.57	0.51	2.40	0.40	1.15	0.26
DP						
Right	2.49	0.45	2.50	0.33	-0.11	0.92
Left	2.66	0.42	2.57	0.34	0.72	0.48
MC						
Right	2.66	0.53	2.59	0.41	0.47	0.64
Left	2.07	0.46	1.78	0.30	2.21	0.03*
DC						
Right	2.77	0.58	2.73	0.39	0.28	0.78
Left	2.40	0.45	2.19	0.46	1.39	0.17
AVS						
Right	2.19	0.47	2.09	0.37	0.73	0.47
Left	1.86	0.42	1.67	0.35	1.65	0.11
Amygdala						
Right	1.64	0.55	1.52	0.43	0.79	0.44
Left	1.63	0.76	1.47	0.43	0.88	0.39
Insula						
Right	0.70	0.13	0.69	0.14	-0.42	0.68
Left	0.69	0.12	0.68	0.16	-1.40	0.17
ACC						
Bilateral	1.02	0.23	1.03	0.23	-0.45	0.66

ACC, anterior cingulate cortex; AVS, anteroventral striatum; DC, dorsal caudate; DP, dorsal putamen; MC, middle caudate; VP, ventral putamen.

The *a priori* hypothesis was tested in the striatal regions-of-interest (caudate, putamen). * $p < 0.05$: D₁ receptor binding was significantly lower in the left middle caudate of the MDD group relative to the control group. Analyses of D₁ receptor binding in extrastriatal tissues were performed *post hoc*.

Age correlated with BP_{ND} in the left VP ($\rho = -0.34$, $p = 0.04$), left DP ($\rho = -0.33$, $p = 0.04$), right MC ($\rho = -0.38$, $p = 0.02$), bilateral DC (left: $\rho = -0.39$, $p = 0.02$; right: $\rho = -0.38$, $p = 0.02$), and left insula ($\rho = -0.42$, $p = 0.01$). The relationship between BP_{ND} and age showed a trend toward significance in right VP ($\rho = -0.32$, $p = 0.06$), left MC ($\rho = -0.29$, $p = 0.08$), and left insula ($\rho = -0.32$, $p = 0.052$) but did not approach significance ($p > 0.10$) in the right DP, AVS, ACC, or amygdala. Analyses were covaried for age where relevant.

A main effect of gender on BP_{ND} was significant in the AVS ($F = 4.21$, $p = 0.048$), VP ($F = 7.28$, $p = 0.043$), MC ($F = 9.72$, $p = 0.026$), and DC ($F = 9.77$, $p = 0.026$) but not in the DP ($F = 1.38$, $p = 0.249$). There were no significant group-by-gender interactions in any region ($p > 0.1$).

Exploratory, *post hoc* clinical correlations showed that BP_{ND} values in the left MC correlated inversely with illness duration ($r = -0.53$, $p = 0.02$; Figure 5), but did not correlate significantly with depression (MADRS), anxiety (HAM-A), or anhedonia (IDS-C anhedonia subscale) severity (ie $p > 0.05$). Reaction times on the RVIP correlated




Figure 1 Dopamine D₁ receptor binding potential in healthy control and major depressive disorder (MDD) groups in the left and right hemispheres for the striatal regions-of-interest. * $p < 0.05$: D₁ receptor binding was significantly lower in the left middle caudate (MC) in the MDD group relative to control group. ** $p < 0.05$, *** $p < 0.001$: the main effect of hemisphere on binding potential (BP_{ND}) was significant in the anteroventral striatum (AVS), ventral putamen (VP), dorsal putamen (DP), middle caudate (MC), and dorsal caudate (DC) regions-of-interest.




Figure 2 Representative parametric dopamine D₁ receptor binding potential (BP_{ND}) images through the striatum in a control subject (left panel) and an major depressive disorder (MDD) subject (right panel). Within each panel the upper row of images show axial (left) and coronal (right) sections through the anatomical MRI, on which the regions-of-interest (ROI) were defined (Drevets et al, 2001), and the lower row of images show parametric images of the nondisplaceable component of the D₁ receptor BP_{ND} modeled from PET emission images. The MRI and PET images for each subject are coregistered. The axial images show the plane containing both the anterior and posterior commissures. The orthogonal lines locate approximately the center of the caudate head on this bicommissural plane. The coronal sections pass through the anterior striatum, which at the level shown is composed predominantly of the caudate head. The middle caudate region is evident in the coronal sections, where it is situated immediately above the bicommissural plane (marked by the horizontal line). The D₁ receptor BP_{ND} consistently was higher in the right caudate than the left in both groups (Figures 1 and 3), as evinced in these representative images. The mean BP_{ND} value in the left middle caudate of the MDD group was lower than in the control group (Figure 1).




Figure 3 Dopamine D₁ receptor binding potential in the left and right hemispheres for each striatal region-of-interest showing the consistency of laterality effects. The left- and right-sided values corresponding to a single participant are connected by a line. Main effects of hemisphere on regional binding potentials were significant in all five regions-of-interest (see Figure 1 and 'Results' section for significance levels).




Figure 4 Mean (\pm SEM) binding potential values for the right and left dorsal putamen separated by sex and diagnosis. In women with major depressive disorder (MDD) the difference in D₁ receptor binding potential (BP_{ND}) between the right and left hemispheres of the dorsal putamen was significantly less than that of the female controls. In the dorsal putamen the group-by-gender-by-hemisphere interaction was significant ($F=7.33$, $p=0.011$). Abbreviations: HC, healthy control; MDD, major depressive disorder.

negatively with D₁ receptor binding in the left MC in controls ($r=-0.453$, $p=0.007$) but not MDD subjects ($r=-0.096$, $p=0.358$). The ratio of left-to-right BP_{ND} values in the MC correlated inversely with IDS-C anhedonia subscale ratings ($r=-0.65$, $p=0.0040$) but not with depression or anxiety ratings ($p>0.4$). MDD subjects with comorbid phobias did not differ in D₁ receptor BP_{ND} in the left MC than nonphobic depressives.

Depression severity correlated negatively with BP_{ND} in right DP (MADRS $\rho=-0.61$, $p=0.007$; Figure 6). Anxiety severity (HAM-A) correlated negatively with BP_{ND} in right DP ($\rho=-0.48$, $p=0.045$). Anhedonia ratings, age at onset, and illness duration did not correlate significantly with BP_{ND} in the DP ($p>0.05$). In right DP, MDD subjects with

comorbid phobias showed lower D₁ receptor BP_{ND} than nonphobic depressives ($Z=-2.3$, $p=0.019$).

Mean BP_{ND} values for depressed subjects who previously were exposed to psychotropic medications ($n=7$) showed no significant difference *vs* drug-naïve subjects ($n=11$) in any region ($p>0.10$).

DISCUSSION

The mean D₁ receptor binding was 14% lower in the left MC of MDD subjects *vs* healthy controls (Figure 1). Moreover, although significant differences in D₁ receptor binding between the right and left hemispheres existed in controls, this normal asymmetry was absent in the DP in depressed women (Figure 4). *Post hoc* assessments in the MDD sample showed that D₁ receptor binding in the left MC correlated inversely with illness duration and anhedonia ratings. In addition, the left MC D₁ receptor binding correlated inversely with psychomotor speed in the controls but not the depressives.

The abnormalities in striatal BP_{ND} in MDD likely reflect alterations in D₁ receptor density and/or affinity for [¹¹C]NNC-112. Although [¹¹C]NNC-112 binding is reversible *in vivo* (Abi-Dargham *et al*, 2000), it is insensitive to displacement by endogenous dopamine (Chou *et al*, 1999). Among DA receptors NNC-112 is highly selective for D₁ receptors (eg the D₁:D₂ receptor binding ratio = 4500) (Ekelund *et al*, 2007). The major limitation in specificity is that [¹¹C]NNC-112 is only 2- to 3-fold more selective for D₁ receptors than 5-HT_{2A} receptors (Ekelund *et al*, 2007). Thus in the frontal cortex, where the 5-HT_{2A} receptor and D₁ receptor concentrations are comparable, up to 25% of [¹¹C]NNC-112 binding is attributable to 5-HT_{2A} receptor binding (Ekelund *et al*, 2006; Slifstein *et al*, 2007). In the striatum, however, where the ratio of D₁:5-HT_{2A} receptor density is relatively higher, the 5-HT_{2A} contribution to the measured BP_{ND} is negligible (Slifstein *et al*, 2007). Thus, the abnormalities observed in the MC and DP in MDD most likely reflect differences in D₁ receptor binding.

The mean 14% decrement in D₁ receptor BP_{ND} in the left MC in our MDD subjects appeared consistent with the 13% reduction in binding in the left striatum reported by Dougherty *et al* (2006) in MDD subjects with anger attacks. Our data extended this previous finding by showing that the left striatal D₁ receptor binding was also decreased in a depressed sample selected more generally according to MDD criteria. We did not observe any abnormality in the right striatum, however, raising the possibility that a deficit in right striatal D₁ receptor binding may be specific to MDD subjects with anger attacks.

Our data more specifically localized the abnormality in left striatal D₁ receptor binding in MDD to the left MC, which showed the greatest magnitude-of-difference and effect size across the striatal ROI (Figures 1 and 3). Because of the proximity of the MC to other striatal ROI, measured signals from the MC were weakly influenced by those from the AVS and DC which were partly continuous with the MC (Drevets *et al*, 1999, 2001). As parts of these ROI were

separated by less than 6 mm resolution of our PET measures, demonstrating differential regional abnormalities in MDD depended upon showing that the mean difference in BP_{ND} was greater in the MC than in the DCA or AVS. This approach was facilitated by the low [¹¹C]NNC-112-specific binding in extrastriatal areas, which reduced the number of comparisons required across adjacent regions. The ability to assess relative differences in radiotracer concentration across conditions in ROI separated by less than the FWHM resolution is central to PET's utility in localizing voxels of maximal difference in brain mapping studies (Fox *et al*, 1986; Friston *et al*, 1996). Because of these spatial resolution limitations, however, the nonsignificant trends seen in the left AVS and left DC (Figure 1) are difficult to interpret as they may reflect spilling in of radioactivity from the MC (Links *et al*, 1996).

The MC region is the major striatal target of predominantly ipsilateral, afferent projections from the ACC and orbitofrontal cortex (OFC) (Ferry *et al*, 2000; Haber *et al*, 2006). As the grey matter volume and/or neuronal counts in these cortical areas is reduced in MDD (Drevets *et al*, 2008), the regional specificity of the reduction in D₁ receptor binding to the MC raises the possibility that this abnormality reflects a reduction in afferent neuronal terminals from the cortex, and thus in the density of synapses where D₁ receptors are expressed postsynaptically. This hypothesis appears compatible with findings that in MDD both the reduction in D₁ receptor binding in the MC (Figure 1) and the reduction in grey matter volume in the ACC and OFC are predominantly left-lateralized (Drevets *et al*, 2008). This hypothesis may also be compatible with the finding that the D₁ receptor binding in the left MC correlated inversely with illness duration (Figure 5), as the reductions in ACC volume reportedly worsen across time in mood disorders (Koo *et al*, 2008). In contrast, perturbations in D₁ receptor binding in MDD may be less likely to reflect local changes in receptor expression associated with changes in DA release, as the severe DA deficiency state accompanying Parkinson's Disease is not associated with changes in D₁ receptor binding or density (Pimoule *et al*, 1985; Shinotoh *et al*, 1993). Moreover, although changes in D₁ receptor regulation at the level of G-protein coupling may exist in the DA-depleted striatum (Gerfen *et al*, 2002),




Figure 5 Relationship between dopamine D₁ receptor binding potential in the left middle caudate and illness duration in the major depressive disorder (MDD) sample. The D₁ receptor binding potential in the left middle caudate correlated inversely ($r = -0.531$, $p = 0.02$) with illness duration (calculated as time since onset of illness).




Figure 6 Relationships between age and D₁ receptor binding potential (BP_{ND}) in the middle caudate and ventral putamen for all subjects. Age correlated negatively with [¹¹C]NNC-112 BP_{ND} in the middle caudate, ventral putamen, and most of other striatal regions examined ($\rho = -0.33$ to -0.42 , $p = 0.01$ – 0.04 ; see text).

such a change would not likely be evinced by corresponding changes in D₁ receptor antagonist binding to PET radioligands (Pimoule *et al*, 1985; Shinotoh *et al*, 1993) which typically bind to receptors in high vs low-affinity states with comparable potency.

Post hoc analyses revealed an altered interhemispheric ratio of D₁ receptor BP_{ND} that differed significantly between depressed and control women in the DP. Specifically, the depressed women showed a loss of the asymmetry in D₁ receptor binding that was evident in the controls (Figure 4). This difference was explained by D₁ receptor BP_{ND} values that were nonsignificantly lower in the left DP and nonsignificantly higher in the right DP in depressed women vs control women (Figure 4).

In other striatal regions the D₁ receptor binding also showed highly significant laterality effects in healthy controls, which did not differ significantly between groups. In the caudate and AVS (accumbens area), the BP_{ND} was lower in the left hemisphere than the right. In contrast, in the putamen the direction of the laterality effect was reversed (left > right). This difference between caudate and putamen may explain the absence of laterality effects in striatal [¹¹C]SCH-23390 binding in Dougherty *et al* (2006), who combined caudate and putamen into a single ROI. Other studies employing neuroimaging or autoradiographic techniques to assess D₁ receptor binding in depressed or healthy humans (De Keyser *et al*, 1988; Suhara *et al*, 1991, 1992; Bowden *et al*, 1997) or experimental animals (Cortes *et al*, 1989; Camps *et al*, 1990) did not examine laterality effects.

Asymmetrical D₁ receptor binding across hemispheres is consistent with several reports of lateralized function within the dopaminergic system. The amount of DA release in human striatal subregions in response to unpredicted reward (Martin-Soelch *et al*, 2007), DA release in the rodent caudate during voluntary behavior (Yamamoto *et al*, 1982), and preference for self-stimulation induced by localized amphetamine administration in rats all show prominent laterality effects (Glick *et al*, 1980, 1981). In healthy humans greater D₂ receptor availability in the left relative to the right striatum was associated with greater positive incentive motivation (Tomer *et al*, 2008). In right-handed humans DA concentrations were higher in the left putamen than the right (Glick *et al*, 1982; de la Fuente-Fernandez *et al*, 2000), and in marmosets levels of DA and HVA were higher in the right caudate and putamen than the left (Silva *et al*, 2007). Consistent with these data humans also showed higher dopamine transporter density in the left putamen and caudate vs the right, irrespective of handedness (van Dyck *et al*, 2002). (Although the lateralization of motor dominance ('handedness') has been associated with variation in elements of the dopaminergic system including COMT (Savitz *et al*, 2007), it remains unclear whether handedness also would influence D₁ receptor BP_{ND}.) Finally, our finding that the loss of normal asymmetry in D₁ receptor BP_{ND} in MDD appeared specific to women was notable given evidence that the direction of asymmetry preference for self-stimulation in rats showed prominent sex effects (Glick and Badalamenti, 1986).

As the mesocorticolimbic dopaminergic system is important in the neural processing of reward and motivation, it is conceivable that either a deficit in dopaminergic function in the left MC, or alterations in the interhemispheric ratio of D₁ receptors that may result from such a

deficit, may disrupt the normally lateralized function of this system and thereby contribute to the depressed mood, anhedonia, and amotivation associated with MDD (Nestler and Carlezon, 2006; Liu *et al*, 2008). Compatible with this hypothesis, the ratio of left-to-right D₁ receptor binding in the MC correlated inversely with the IDS-C anhedonia subscale ($r = -0.65$, $p = 0.0040$). In the left MC functional abnormalities have been identified during reward processing in MDD. In independent samples of MDD subjects the magnitude of DA release during unpredicted monetary reward and the hemodynamic response to anticipated monetary reward were abnormally blunted specifically in the left MC (Drevets, 2008).

The relationship between the response latencies on a sustained attention task (RVIP) and D₁ receptor binding in the left MC in healthy controls suggests that the abnormal D₁ binding group in MDD also may play a role in the psychomotor or cognitive impairment associated with MDD. The mean response latency was 12% slower in depressives than controls, as expected (Tavares *et al*, 2003), although we were underpowered to establish the statistical significance of this difference. Although reaction times measured on the RVIP reflect both psychomotor speed and sustained attention, these variables generally are confounded on neuropsychological assessments of psychomotor speed. In controls the response latencies correlated inversely with BP_{ND} in the left MC (explaining 20.5% of the variance) implying the reduction in D₁ receptor binding in this region in MDD may contribute to the psychomotor slowing associated with depression. The absence of a normal correlation between reaction time and MC-BP_{ND} in the MDD group also may be compatible with this hypothesis. Notably, psychomotor slowing previously was associated with reduced dopaminergic function in the left caudate in MDD, as (Martinot *et al*, 2001) reported that [¹⁸F]DOPA was reduced specifically in the left caudate in MDD patients with psychomotor retardation compared to both healthy controls and MDD patients without psychomotor slowing.

The inverse correlation between D₁ receptor binding and age is consistent with the results of previous PET (Suhara *et al*, 1991; Iyo and Yamasaki, 1993; Wang *et al*, 1998) or autoradiography studies (Klimek *et al*, 2002) conducted in humans or experimental animals (Suzuki *et al*, 2001). In humans Wang *et al*, (1998) reported a 6–7% decline in [¹¹C]SCH-23390 binding to D₁ receptors per decade in the caudate and putamen, comparable to the 3–6% decline in the BP_{ND} for [¹¹C]NNC-112 per decade detected herein (assessed relative to the y -intercept for predicted value at birth; Figure 6). In contrast, the relationship between BP_{ND} and age was not significant in the amygdala, consistent with the data of Klimek *et al*. (2002) who observed no significant age effect on D₁ receptor density measured *post mortem* in the human amygdala.

A limitation of our study was that we modeled the BP_{ND} for [¹¹C]NNC-112 using a simplified reference tissue model to avoid arterial cannulation. This approach used the time-tissue radioactivity concentration in a reference region, the cerebellum, to estimate the concentration of free plus nonspecifically bound radiotracer in all regions. However, without arterial plasma we were unable to measure the distribution volume of [¹¹C]NNC-112 in the cerebellum.

Consequently, a difference in BP_{ND} between groups could have been accounted for by abnormal [¹¹C]NNC-112 binding either in the region-of-interest or the reference tissue. However, an abnormality of tracer uptake in the reference tissue could not account for the regionally specific group difference or the group-by-gender-by-hemisphere interaction found in the left MC and the DP, respectively.

In conclusion, reduced D₁ receptor binding in the left MC, and in women an altered symmetry in D₁ receptor binding in the DP, may contribute to dysfunction within the central dopaminergic system during depression. The prominent laterality effects we observed for striatal D₁ receptor binding converges with other evidence indicating that DA concentrations are lateralized within the striatum (Glick *et al*, 1982; de la Fuente-Fernandez *et al*, 2000; Silva *et al*, 2007), and that the function of the central dopaminergic system in the striatum is lateralized during reward processing (Martin-Soelch *et al*, 2007), voluntary movement (Yamamoto *et al*, 1982), and self-stimulation behavior (Glick *et al*, 1980, 1981; Glick and Badalamenti, 1986). As dopaminergic projections into the striatum modulate the neural processing of reward learning, motivated behavior, and psychomotor activity, alterations in the interhemispheric ratio of D₁ receptor binding conceivably may disrupt the normally lateralized function of this system, and thereby contribute to the depressed mood, psychomotor slowing, anhedonia, and amotivation that characterize depression.

ACKNOWLEDGEMENTS

We acknowledge Victor Pike, Robert Innis, and Masahiro Fujita for providing the radioligand, Peter Herscovitch, MD and the Clinical Center PET Department for Technical Assistance, Michele Drevets, RN and Joan Williams, RN, for evaluation and recruitment of the research subjects, the staff of the NIH Clinical Center, Allison Nugent, Stephen Fromm, Summer Peck, Suzanne Wood, Kelly Anastasi, and Laurentina Cizza for assistance in data management, and Dave Luckenbaugh, PhD for advice regarding the statistical analysis of the PET data. This study was supported by the intramural research program of the NIH/NIMH and a National Alliance for Research on Schizophrenia and Depression Young Investigator Award.

DISCLOSURE/CONFLICT OF INTEREST

No author has a potential conflict of interest related to this work.

REFERENCES

Abi-Dargham A, Martinez D, Mawlawi O, Simpson N, Hwang DR, Slifstein M *et al* (2000). Measurement of striatal and extrastriatal dopamine D₁ receptor binding potential with [¹¹C]NNC 112 in humans: validation and reproducibility. *J Cereb Blood Flow Metab* **20**: 225–243.

Agren H, Reibring L (1994). PET studies of presynaptic monoamine metabolism in depressed patients and healthy volunteers. *Pharmacopsychiatry* **27**: 2–6.

Andersen PH, Gronvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C *et al* (1992). NNC-112, NNC-687 and NNC-756, new

selective and highly potent dopamine D₁ receptor antagonists. *Eur J Pharmacol* **219**: 45–52.

APA (1994). *Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)*. APA Press: Washington, DC.

Argyelan M, Szabo Z, Kanyo B, Tanacs A, Kovacs Z, Janka Z *et al* (2005). Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. *J Affect Disord* **89**: 115–123.

Arnsten AF, Cai JX, Murphy BL, Goldman-Rakic PS (1994). Dopamine D₁ receptor mechanisms in the cognitive performance of young adult and aged monkeys. *Psychopharmacology (Berl)* **116**: 143–151.

Asberg M, Bertilsson L, Martensson B (1984). CSF monoamine metabolites, depression, and suicide. *Adv Biochem Psychopharmacol* **39**: 87–97.

Bowden C, Theodorou A, Cheetham SC, Lowther S, Katona CL, Crompton MR *et al* (1997). Dopamine D₁ and D₂ receptor binding sites in brain samples from depressed suicides and controls. *Brain Res* **752**: 227–233.

Bremner JD, Vythilingam M, Ng CK, Vermetten E, Nazeer A, Oren DA *et al* (2003). Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression. *JAMA* **289**: 3125–3134.

Brunswick DJ, Amsterdam JD, Mozley PD, Newberg A (2003). Greater availability of brain dopamine transporters in major depression shown by [99 m Tc]TRODAT-1 SPECT imaging. *Am J Psychiatry* **160**: 1836–1841.

Camps M, Kelly PH, Palacios JM (1990). Autoradiographic localization of dopamine D₁ and D₂ receptors in the brain of several mammalian species. *J Neural Transm Gen Sect* **80**: 105–127.

Cannon DM, Ichise M, Rollis D, Klaver JM, Gandhi SK, Charney DS *et al* (2007). Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [(11)C]DASB; comparison with bipolar disorder. *Biol Psychiatry* **62**: 870–877.

Chou YH, Karlsson P, Halldin C, Olsson H, Farde L (1999). A PET study of D₁-like dopamine receptor ligand binding during altered endogenous dopamine levels in the primate brain. *Psychopharmacology (Berl)* **146**: 220–227.

Cortes R, Gueye B, Pazos A, Probst A, Palacios JM (1989). Dopamine receptors in human brain: autoradiographic distribution of D₁ sites. *Neuroscience* **28**: 263–273.

De Keyser J, Dierckx R, Vanderheyden P, Ebinger G, Vauquelin G (1988). D₁ dopamine receptors in human putamen, frontal cortex and calf retina: differences in guanine nucleotide regulation of agonist binding and adenylate cyclase stimulation. *Brain Res* **443**: 77–84.

de la Fuente-Fernandez R, Kishore A, Calne DB, Ruth TJ, Stoessl AJ (2000). Nigrostriatal dopamine system and motor lateralization. *Behav Brain Res* **112**: 63–68.

de la Mora MP, Cardenas-Cachon L, Vazquez-Garcia M, Crespo-Ramirez M, Jacobsen K, Hoistad M *et al* (2005). Anxiolytic effects of intra-amygdaloid injection of the D₁ antagonist SCH23390 in the rat. *Neurosci Lett* **377**: 101–105.

Den Boer JA, van Megen HJ, Fleischhacker WW, Louwerens JW, Slaap BR, Westenberg HG *et al* (1995). Differential effects of the D₁-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. *Psychopharmacology (Berl)* **121**: 317–322.

Dougherty DD, Bonab AA, Ottowitz WE, Livni E, Alpert NM, Rauch SL *et al* (2006). Decreased striatal D₁ binding as measured using PET and [¹¹C]SCH 23390 in patients with major depression with anger attacks. *Depress Anxiety* **23**: 175–177.

Drevets W, Gadde K, Krishnan K (2005). Neuroimaging studies of mood disorders. In: Charney D, Nestler E (eds). *The Neurobiology of Mental Illness*, 2 edn.

- Drevets W (2008). Neural circuits underlying anhedonia in major depressive disorder. *Biol Psychiatry* 63(7 supplement 1): 110S.
- Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA *et al* (2001). Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. *Biol Psychiatry* 49: 81–96.
- Drevets WC, Price JC, Kupfer DJ, Kinahan PE, Lopresti B, Holt D *et al* (1999). PET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum. *Neuropsychopharmacology* 21: 694–709.
- Drevets WC, Price JL, Furey ML (2008). Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. *Brain Struct Funct* 213: 93–118.
- Ebert D, Feistel H, Loew T, Pirner A (1996). Dopamine and depression—striatal dopamine D₂ receptor SPECT before and after antidepressant therapy. *Psychopharmacology (Berl)* 126: 91–94.
- Ekelund J, Narendran R, Guillain O, Castrillon J, Hwang D, Slifstein M *et al* (2006). Pharmacological selectivity of the *in vivo* binding of [11C]NNC 112 and [11C]SCH 23390 in the cortex. A PET study in baboons. *Neuroimage* 31(Suppl 2): T111.
- Ekelund J, Slifstein M, Narendran R, Guillain O, Belani H, Guo NN *et al* (2007). *In vivo* DA D (1) receptor selectivity of NNC 112 and SCH 23390. *Mol Imaging Biol* 9: 117–125.
- El-Ghundi M, Fletcher PJ, Drago J, Sibley DR, O'Dowd BF, George SR (1999). Spatial learning deficit in dopamine D (1) receptor knockout mice. *Eur J Pharmacol* 383: 95–106.
- El-Ghundi M, O'Dowd BF, George SR (2001). Prolonged fear responses in mice lacking dopamine D₁ receptor. *Brain Res* 892: 86–93.
- Ferry AT, Ongur D, An X, Price JL (2000). Prefrontal cortical projections to the striatum in macaque monkeys: evidence for an organization related to prefrontal networks. *J Comp Neurol* 425: 447–470.
- Fibiger HC (1991). The dopamine hypothesis of schizophrenia and mood disorders. In: Willner P, Scheel-Kruger J (eds). *The Mesolimbic Dopamine System: From Motivation to Action*. Wiley: New York. pp 615–638.
- Fox PT, Mintun MA, Raichle ME, Miezin FM, Allman JM, Van Essen DC (1986). Mapping human visual cortex with positron emission tomography. *Nature* 323: 806–809.
- Friston KJ, Holmes A, Poline JB, Price CJ, Frith CD (1996). Detecting activations in PET and fMRI: levels of inference and power. *Neuroimage* 4: 223–235.
- Gerfen CR, Miyachi S, Paletzki R, Brown P (2002). D₁ dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. *J Neurosci* 22: 5042–5054.
- Glick SD, Badalamenti JJ (1986). Sex difference in reward asymmetry and effects of cocaine. *Neuropharmacology* 25: 633–637.
- Glick SD, Ross DA, Hough LB (1982). Lateral asymmetry of neurotransmitters in human brain. *Brain Res* 234: 53–63.
- Glick SD, Weaver LM, Meibach RC (1980). Lateralization of reward in rats: differences in reinforcing thresholds. *Science* 207: 1093–1095.
- Glick SD, Weaver LM, Meibach RC (1981). Amphetamine enhancement of reward asymmetry. *Psychopharmacology (Berl)* 73: 323–327.
- Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ, Robbins TW (2000). Enhanced and impaired attentional performance after infusion of D₁ dopaminergic receptor agents into rat prefrontal cortex. *J Neurosci* 20: 1208–1215.
- Haber SN, Kim KS, Mailly P, Calzavara R (2006). Reward-related cortical inputs define a large striatal region in primates that interface with associative cortical connections, providing a substrate for incentive-based learning. *J Neurosci* 26: 8368–8376.
- Halldin C, Foged C, Chou YH, Karlsson P, Swahn CG, Sandell J *et al* (1998). Carbon-11-NNC 112: a radioligand for PET examination of striatal and neocortical D₁-dopamine receptors. *J Nucl Med* 39: 2061–2068.
- Hamilton M (1959). The assessment of anxiety states by rating. *Brit J Med Psychol* 32: 50–55.
- Hasler G, Fromm S, Carlson PJ, Luckenbaugh DA, Waldeck T, Geraci M *et al* (2008). Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. *Arch Gen Psychiatry* 65: 521–531.
- Hirvonen J, Karlsson H, Kajander J, Markkula J, Rasi-Hakala H, Nagren K *et al* (2008). Striatal dopamine D₂ receptors in medication-naïve patients with major depressive disorder as assessed with [11C]raclopride PET. *Psychopharmacology (Berl)* 197: 581–590.
- Holmes A, Lachowicz JE, Sibley DR (2004). Phenotypic analysis of dopamine receptor knockout mice; recent insights into the functional specificity of dopamine receptor subtypes. *Neuropharmacology* 47: 1117–1134.
- Huang YY, Simpson E, Kellendonk C, Kandel ER (2004). Genetic evidence for the bidirectional modulation of synaptic plasticity in the prefrontal cortex by D₁ receptors. *Proc Natl Acad Sci USA* 101: 3236–3241.
- Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H *et al* (2003). Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. *J Cereb Blood Flow Metab* 23: 1096–1112.
- Iyo M, Yamasaki T (1993). The detection of age-related decrease of dopamine D₁, D₂ and serotonin 5-HT₂ receptors in living human brain. *Prog Neuropsychopharmacol Biol Psychiatry* 17: 415–421.
- Jenkinson M, Smith S (2001). A global optimisation method for robust affine registration of brain images. *Med Image Anal* 5: 143–156.
- Karle J, Clemmesen L, Hansen L, Andersen M, Andersen J, Fensbo C *et al* (1995). NNC 01-0687, a selective dopamine D₁ receptor antagonist, in the treatment of schizophrenia. *Psychopharmacology (Berl)* 121: 328–329.
- Kato T (2007). Molecular genetics of bipolar disorder and depression. *Psychiatry Clin Neurosci* 61: 3–19.
- Klimek V, Schenck JE, Han H, Stockmeier CA, Ordway GA (2002). Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. *Biol Psychiatry* 52: 740–748.
- Klimke A, Larisch R, Janz A, Vosberg H, Muller-Gartner HW, Gaebel W (1999). Dopamine D₂ receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT. *Psychiatry Res* 90: 91–101.
- Koks S, Nikopensius T, Koido K, Maron E, Altnae S, Heinaste E *et al* (2006). Analysis of SNP profiles in patients with major depressive disorder. *Int J Neuropsychopharmacol* 9: 167–174.
- Koo MS, Levitt JJ, Salisbury DF, Nakamura M, Shenton ME, McCarley RW (2008). A cross-sectional and longitudinal magnetic resonance imaging study of cingulate gyrus gray matter volume abnormalities in first-episode schizophrenia and first-episode affective psychosis. *Arch Gen Psychiatry* 65: 746–760.
- Lalumiere RT, Nguyen LT, McGaugh JL (2004). Post-training intrabasolateral amygdala infusions of dopamine modulate consolidation of inhibitory avoidance memory: involvement of noradrenergic and cholinergic systems. *Eur J Neurosci* 20: 2804–2810.
- Lambert G, Johansson M, Agren H, Friberg P (2000). Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. *Arch Gen Psychiatry* 57: 787–793.
- Laruelle M, Huang Y (2001). Vulnerability of positron emission tomography radiotracers to endogenous competition. New insights. *Q J Nucl Med* 45: 124–138.
- Links JM, Zubieta JK, Meltzer CC, Stumpf MJ, Frost JJ (1996). Influence of spatially heterogeneous background activity on hot object quantitation in brain emission computed tomography. *J Comput Assist Tomogr* 20: 680–687.

- Liu ZH, Shin R, Ikemoto S (2008). Dual role of medial A10 dopamine neurons in affective encoding. *Neuropsychopharmacology*. February 6, 2008; [epub ahead of print] doi: 10.1038/npp.2008.4)
- Martinot M, Bragulat V, Artiges E, Dolle F, Hinnen F, Jouvent R et al (2001). Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. *Am J Psychiatry* 158: 314–316.
- Martin-Soelch C, Infante A, Szczepanik J, Nugent A, Cannon D, Herscovitch P et al (2007). Lateralized dopaminergic response to reward in the human ventral striatum. *Society for Neuroscience*. p.311.315/FFF318.
- Meyer JH, Kruger S, Wilson AA, Christensen BK, Goulding VS, Schaffer A et al (2001). Lower dopamine transporter binding potential in striatum during depression. *Neuroreport* 12: 4121–4125.
- Mikolajczyk K, Szabatin M, Rudnicki P, Grodzki M, Burger C (1998). A JAVA environment for medical image data analysis: initial application for brain PET quantitation. *Med Inform (Lond)* 23: 207–214.
- Montgomery AJ, Stokes P, Kitamura Y, Grasby PM (2007). Extrastriatal D2 and striatal D2 receptors in depressive illness: pilot PET studies using [11C]FLB 457 and [11C]raclopride. *J Affect Disord* 101: 113–122.
- Montgomery S, Asberg M (1979). A new depression scale designed to be sensitive to change. *Brit J Psychiat* 134: 382–389.
- Nestler EJ, Carlezon Jr WA (2006). The mesolimbic dopamine reward circuit in depression. *Biol Psychiatry* 59: 1151–1159.
- Nutt DJ, Baldwin DS, Clayton AH, Elgie R, Lecrubier Y, Montejo AL et al (2006). Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. *J Clin Psychiatry* 67(Suppl 6): 46–49.
- Ongur D, Ferry AT, Price JL (2003). Architectonic subdivision of the human orbital and medial prefrontal cortex. *J Comp Neurol* 460: 425–449.
- Papp M, Klimek V, Willner P (1994). Parallel changes in dopamine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. *Psychopharmacology (Berl)* 115: 441–446.
- Parsey RV, Oquendo MA, Zea-Ponce Y, Rodenhiser J, Kegeles LS, Prapat M et al (2001). Dopamine D (2) receptor availability and amphetamine-induced dopamine release in unipolar depression. *Biol Psychiatry* 50: 313–322.
- Pimoule C, Schoemaker H, Reynolds GP, Langer SZ (1985). [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. *Eur J Pharmacol* 114: 235–237.
- Robbins TW (2000). Chemical neuromodulation of frontal-executive functions in humans and other animals. *Exp Brain Res* 133: 130–138.
- Romach MK, Glue P, Kampman K, Kaplan HL, Somer GR, Poole S et al (1999). Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166). *Arch Gen Psychiatry* 56: 1101–1106.
- Savitz J, van der Merwe L, Solms M, Ramesar R (2007). Lateralization of hand skill in bipolar affective disorder. *Genes Brain Behav* 6: 698–705.
- Schultz W (1997). Dopamine neurons and their role in reward mechanisms. *Curr Opin Neurobiol* 7: 191–197.
- Severino G, Congiu D, Serrelli C, De Lisa R, Chillotti C, Del Zompo M et al (2005). A48G polymorphism in the D1 receptor genes associated with bipolar I disorder. *Am J Med Genet B Neuropsychiatr Genet* 134B: 37–38.
- Shinotoh H, Inoue O, Hirayama K, Aotsuka A, Asahina M, Suhara T et al (1993). Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study. *J Neurol Neurosurg Psychiatry* 56: 467–472.
- Silva MA, Topic B, Lamounier-Zepter V, Huston JP, Tomaz C, Barros M (2007). Evidence for hemispheric specialization in the marmoset (*Callithrix penicillata*) based on lateralization of behavioral/neurochemical correlations. *Brain Res Bull* 74: 416–428.
- Slifstein M, Kegeles LS, Gonzales R, Frankle WG, Xu X, Laruelle M et al (2007). [11C]NNC 112 selectivity for dopamine D1 and serotonin 5-HT (2A) receptors: a PET study in healthy human subjects. *J Cereb Blood Flow Metab* 27: 1733–1741.
- Suhara T, Fukuda H, Inoue O, Itoh T, Suzuki K, Yamasaki T et al (1991). Age-related changes in human D1 dopamine receptors measured by positron emission tomography. *Psychopharmacology (Berl)* 103: 41–45.
- Suhara T, Nakayama K, Inoue O, Fukuda H, Shimizu M, Mori A et al (1992). D1 dopamine receptor binding in mood disorders measured by positron emission tomography. *Psychopharmacology (Berl)* 106: 14–18.
- Suzuki M, Hatano K, Sakiyama Y, Kawasumi Y, Kato T, Ito K (2001). Age-related changes of dopamine D1-like and D2-like receptor binding in the F344/N rat striatum revealed by positron emission tomography and *in vitro* receptor autoradiography. *Synapse* 41: 285–293.
- Swerdlow NR, Koob GF (1987). Dopamine, schizophrenia, mania, and depression: toward a unified hypothesis of cortico-striato-thalamic function. *Behav Brain Sci* 10: 197–245.
- Tavares JV, Drevets WC, Sahakian BJ (2003). Cognition in mania and depression. *Psychol Med* 33: 959–967.
- Todd RD, Carl J, Harmon S, O'Malley KL, Perlmutter JS (1996). Dynamic changes in striatal dopamine D2 and D3 receptor protein and mRNA in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) denervation in baboons. *J Neurosci* 16: 7776–7782.
- Tomer R, Goldstein RZ, Wang GJ, Wong C, Volkow ND (2008). Incentive motivation is associated with striatal dopamine asymmetry. *Biol Psychol* 77: 98–101.
- van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM et al (2002). Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. *Am J Geriatr Psychiatry* 10: 36–43.
- Waddington JL, Clifford JJ, McNamara FN, Tomiyama K, Koshikawa N, Croke DT (2001). The psychopharmacology-molecular biology interface: exploring the behavioural roles of dopamine receptor subtypes using targeted gene deletion ('knockout'). *Prog Neuropsychopharmacol Biol Psychiatry* 25: 925–964.
- Wang Y, Chan GL, Holden JE, Dobko T, Mak E, Schulzer M et al (1998). Age-dependent decline of dopamine D1 receptors in human brain: a PET study. *Synapse* 30: 56–61.
- Williams GV, Goldman-Rakic PS (1995). Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. *Nature* 376: 572–575.
- Willner P (1995). Dopaminergic mechanisms in depression and mania. In: Bloom FE, Kupfer DJ (eds). *Psychopharmacology: The Fourth Generation of Progress*. Raven Press: New York, pp 921–932.
- Willner P (2000). Dopaminergic mechanisms in depression and mania. In: Bloom FaK, D (ed). *Neuropsychopharmacology. The Fourth Generation of Progress*, Raven Press, New York.
- Wise RA, Rompre PP (1989). Brain dopamine and reward. *Annu Rev Psychol* 40: 191–225.
- Woods RP, Cherry SR, Mazziotta JC (1992). Rapid automated algorithm for aligning and reslicing PET images. *J Comput Assist Tomogr* 16: 620–633.
- Yamamoto BK, Lane RF, Freed CR (1982). Normal rats trained to circle show asymmetric caudate dopamine release. *Life Sci* 30: 2155–2162.
- Yang YK, Yeh TL, Yao WJ, Lee IH, Chen PS, Chiu NT et al (2008). Greater availability of dopamine transporters in patients with major depression—a dual-isotope SPECT study. *Psychiatry Res* 162: 230–235.
- Zarate Jr CA, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD et al (2004). Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. *Biol Psychiatry* 56: 54–60.